<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012911/" ref="ordinalpos=1253&amp;ncbi_uid=6623876&amp;link_uid=PMC4012911" image-link="/pmc/articles/PMC4012911/figure/fig4/" class="imagepopup">Figure 4.  From: Adrenomedullin up-regulates osteopontin and attenuates vascular calcification via the cAMP/PKA <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">ADM upregulates OPN mRNA expression through the cyclic adenosine 3′,5′-monophosphate (cAMP)/protein kinase A (PKA) signaling pathway. Forskolin, an adenylyl cyclase agonist; H89, a PKA inhibitor; Fura-2, a Ca2+ chelator; and PD98059, a mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) inhibitor. cP&lt;0.01 vs Con; eP&lt;0.05 vs ADM 10−7 mol/L.</div></div>